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p16 mutations/deletions are not frequent events in prostate cancer
Y Tamimi, PP Bringuier, F Smit, A van Bokhoven, FMJ Debruyne and JA Schalken
Department of Urology/Urological Research Laboratory, University Hospital Nijmegen, Nijmegen, The Netherlands.
Summary Cyclin-dependent kinase-4 inhibitor gene (pl16'NK4) has recently been mapped to chromosome 9p2l.
Homozygous deletions of this gene have been found at high frequency in cell lines derived from different types
of tumours. These findings suggested therefore, that p161NK4 is a tumour-suppressor gene involved in a wide
variety of human cancers. To investigate the frequency of p16INK4 mutations/deletions in prostate cancer, we
screened 20 primary prostate tumours and four established cell lines by polymerase chain reaction (PCR) and
single-strand conformation polymorphism (SSCP) analysis for exon and exon 2. In contrast to most previous
reports, no homozygous deletions were found in prostate cancer cell lines, but one cell line (DUl45) has
revealed a mutation at codon 76. Only two SSCP shifts were detected in primary tumours: one of them
corresponds to a mutation at codon 55 and the other one probably corresponds to a polymorphism. These data
suggest that mutation of the p16INK4 gene is not a frequent genetic alteration implicated in prostate cancer
development.
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Cyclin-dependent kinases (CDKs) are key enzymes in driving
cells through the cell cycle into mitosis. Their activity is tightly
controlled by phosphorylation and dephosphorylation of the
CDK itself and association with regulatory subunits. Binding
of a specific cyclin is a prerequisite for kinase activity. On the
other hand, CDK inhibitory subunits have been recently
described. p21 and p27 share a region of homology, and form
with CDK and cyclins ternary complexes that can inhibit a
variety of CDKs (Polyak et al., 1994; Nasmyth and Hunt,
1993). p16INK4 was the first identified member (Serrano et al.,
1993) of a growing family of proteins that specifically inhibit
CDK4 and CDK6 (Kamb et al., 1994; Nobori et al., 1994;
Hannon and Beach, 1994). These two CDKs act together with
cyclin D to control Rb phosphorylation and passage through
the starting point of the cell cycle. This is a crucial step in
controlling cell growth and perturbation of this pathway is
thought to be implicated in carcinogenesis (Kamb et al., 1994).
Moreover, the gene encoding p16 protein, (p16NK4/CDKN/
MTSI) has been recently located in the chromosomal region
9p2l, a critical area ofallelic loss in a wide spectrum ofhuman
tumours (Serrano et al., 1993; Kamb et al., 1994; Nobori et al.,
1994). Interestingly, a high frequency ofhomozygous deletions
in the p16INK4 gene in cell lines derived from a variety ofhuman
tumours including bladder and kidney have been reported
(Kamb et al., 1994). The mutation rate found in cell lines could
even rival that ofthe p53 tumour-suppressor gene. However, in
primary tumours the rate of p161NK4 mutations seems to be
rather low and varies in a tumour type-dependent manner
(Mori et al., 1994; Cairns et al., 1994; Spruck et al., 1994).
Here we investigated the alterations of p16NK4 in cell lines
and primary tumours of the prostate using the polymerase
chain reaction (PCR) and single-strand conformation
polymorphism (SSCP) analysis.
Materials and methods
Patient samples, cell lines and DNA isolation
Four established prostatic cell lines (PC3, DU145, TSUprl,
LNCaP) were grown in RPMI medium containing 10% of
calf serum until they reach confluence. DNA was extracted
according to Miller et al. (1988). Twenty prostate cancer
samples of various Gleason grades (Gg2-GgS) were obtained
by transurethral resection of the prostate, and then frozen in
liquid nitrogen. Areas containing at least 70% of tumour cells
as judged by step sectioning, were subjected to DNA
extraction (Miller et al., 1988).
Polymerase chain reaction (PCR)
We amplified exon 1 and exon 2 for the analysis of p16INK4
gene alterations in prostate cancer. Primer sequences used for
amplification were: 5'-GAAGAAGAGGAGGGGCTG-3'
and 5'-GCGCTACCTGATTCCAATTC-3' for exon 1. Two
overlapping primer sets were taken to cover the entire 500 bp
long exon 2: 5'-GCAGCACCACCAGCGTGTCC-3' and 5'-
GGAAATTGGAAACTGGAAGC -3'5'- TCTGTTCTCTCT-
GGCAGGTC -3' and 5'-TCTGAGCTTTGGAAGCTCT -3'.
Purified DNA (50 ng) was amplified in a total volume of
50 pl using 50 pmol of sense and antisense primers, 200 gM
of each dNTP, 1 x amplification buffer (17 mM ammonium
sulphate, 67 mM Tris pH 8.8, 2 mm magnesium chloride,
10 mM P-mercaptoethanol, 6.7 gM EDTA), 2.5 mm magne-
sium chloride for exon 1, 1.5 mM magnesium chloride for
exon 2 and 0.5 pl (2.5 unit) of Taq polymerase (Perkin
Elmer). Dimethyl sulphoxide (5%) was added for each DNA
amplification reaction. For SSCP analysis 0.3 pl [CX-32P]dATP
(370 MBq ml-', -10 TBq mmol-') was added to the
reaction. Forty cycles of 50 s at 94°C, 40s at 61°C, 40 s at
72°C were carried out in a Perkin-Elmer thermal cycler. The
PCR products were subsequently analysed by electrophoresis
on 2% agarose gels.
SSCP analysis
The reaction product (3 Ml) was then mixed with 10 1l of
loading buffer containing 96% formamide. Samples were
denatured at 94°C for 3 min, chilled on ice for at least 5 min
and 2,l was loaded onto a 6% non-denaturing polyacryla-
mide gel with or without 10% glycerol. Gels were
electrophoresed at 5 W (with glycerol) and 3 W (without
glycerol) for 16 h at room temperature, using 0.5 x Tris-
borate-EDTA buffer. Gels were dried and exposed to (RPN
8 35 x 43 cm) Amersham film at - 80°C for 3 days.
Sequence analysis
PCR products displaying a shift on SSCP analysis were
sequenced both directly, as described before (Jacoby et al.,
1994) and after being cloned into TA cloning vector (pCR II;
Invitrogen).
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Results and discussion
We have studied the mutation frequency in the MTS1/pl6INK4
gene, in prostate cancer. Exon 1 and exon 2 represent the
major part of the coding sequence (98% of the p16 protein),
whereas exon 3 makes up only 11 coding nucleotides (2% of
the total coding sequence). Amplification of tumour genomic
DNA using primers for exon 1 and exon 2 of the p16INK4
gene resulted in bands of the predicted size 350, 240 and
340 bp respectively when separated on 2% agarose gel. A
PCR product of the expected size was obtained in each of the
four prostatic cell lines, indicating that none of them has a
homozygous deletion of the p16 gene.
We subsequently investigated the presence of point
mutations in exon 1 and exon 2 fragments of the p161NK4
gene by SSCP analysis, a technique that is sensitive enough to
detect more than 80% of mutations (Sheffield et al., 1993).
The screening of almost the entire coding sequence (98%) of
pl6INK4 revealed band migration shifts, for exon 2, in one cell
line (DU145) and two primary tumours (see example in
Figure 1, sample 21).
The corresponding PCR products were sequenced. This
revealed a missense mutation in DU145 at codon 76
(GAC-.TAC) resulting in a change from aspartic acid to
tyrosine (see example in Figure 2). The shift found in one of
the primary tumours (case 166) was a mutation at codon 55
(CTG-+CCG) leading to a change from leucine to proline.
It remains to be determined whether the substitution of the
Asp with Tyr and Leu with Pro at codons 76 and 55
respectively plays a part in prostate cancer development. The
shift in the other primary tumour (case 154) corresponded to
a GCG-+ACG transition at codon 140 leading to a change
from alanine to threonine. This change was previously
reported and is thought to represent a polymorphism as it
has also been found in white blood cells (Spruck et al.,
1994).
Genetic aberrations involved in prostate cancer have
been taken into consideration previously and partly studied.
Likewise, loss of heterozygosity (LOH) studies, identifying
chromosomal regions harbouring potential tumour-suppres-
sor genes, have mainly revealed 8p, 10q, 13q, 16q and 18q
(Bergerheim et al., 1991; Bova et al., 1993; Phillips et al.,
1994). However, most LOH studies are limited to the
analysis of a few chromosomes leaving the major part of
the genome unexamined. Recently, genetic changes in
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Figure 1 A representative example of SSCP analysis of p161NK4
gene (exon 2) in primary tumour and established cell lines of the
prostate. A migration shift displayed by one primary tumour
(sample 21).
primary and recurrent prostate cancer were analysed by
comparative genomic hybridisation (CGH) (Visakorpi et al.,
1995), a new technique enabling the survey of the entire
genome for gains and losses of DNA sequences (du Manoir
et al., 1993). Losses most often involved 8p (32%), 13q
(32%), 6q (22%), 16q (19%), 18q (19%) and 9p (16%)
(Visakorpi et al., 1995). Hence, the frequency of 9p losses
seems higher than the frequency of p16 mutations we found
in this study, suggesting that another gene is the major
target on 9p.
At present, the role played by the p16INK4 gene in human
cancer remains controversial. For instance, in a recent study
using primary tumours from a variety of organ types, which
were previously shown to have loss of heterozygosity
involving 9p21-p22, p16 mutations were found in less than
3% (Cairns et al., 1994). Mutations within the non-coding
region, rearrangement and down-regulation of p16 could play
a role in the inactivation of this gene in some cases (Cheng et
al., 1994). Furthermore, mutations within the promoter
region may alter the normal expression of the p16 gene,
although this type of mutation has not been reported to be a
predominant mechanism of gene inactivation in human
cancer (Cairns et al., 1994).
Using SSCP-PCR analyses on four established prostatic
cell lines and 20 primary tumours, we were not able to find
more than two mutations: one in the DUI45 cell line, and
one in primary tumours. These results indicate that mutation
of the p16INK4 gene is not a frequent genetic change in the
formation of primary prostate cancer. Moreover, in contrast
to several reports in which homozygous deletion in cultured
cell lines can reach 85% (Kamb et al., 1994), homozygous
deletions in established lines of prostate cancer were not
found in the four analysed cases. Parallel to our
observations on primary prostatic tumours, analysis of
tumours from several organs such as astrocytomas (Ueki
et al., 1994), breast (Xu et al., 1994), bladder (Cairnes et al.,
1994); Spruck et al., 1994), lung, brain and kidney tumours
(Cairns et al., 1994) revealed p16INK4 mutations in only a
small fraction of primary tumours. Alternatively, higher
frequencies have been found in some tumour types: 16% in
head and neck squamous cell carcinoma and up to 51% in
oesophageal squamous cell carcinomas have been detected
recently (Mori et al., 1994). Therefore, the pl6INK4 gene has
certainly a key role in certain cases, but not in all tumour
types.
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Figure 2 A representation of DNA sequencing of the SSCP shift
observed in DU145 prostate cancer cell line. A base substitution
from cytidine to adenosine in the non-coding strand is indicated
by an arrow. This base substitution leads to a change from
guanine to thymine at codon 76 and results in an amino acid
change from aspartic acid to tyrosine.
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